These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 33685082)

  • 1. [The application of Voriconazole in 76 patients with cirrhosis at Child-Pugh C stage complicated by invasive fungal infection].
    Zhang Y; Wang YG; Zhang JC; Zhang YT; Liang JX; Mu JS
    Zhonghua Gan Zang Bing Za Zhi; 2021 Feb; 29(2):137-142. PubMed ID: 33685082
    [No Abstract]   [Full Text] [Related]  

  • 2. [Treatment of Invasive Fungal Infection in Childhood Acute Lymphoblastic Leukemia with Amphotericin B and Voriconazole].
    Yi XL; Mao Q; Jiang Y; Guo XB; Chen Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1627-1630. PubMed ID: 29262887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic drug monitoring and safety of voriconazole therapy in patients with Child-Pugh class B and C cirrhosis: A multicenter study.
    Wang T; Yan M; Tang D; Xue L; Zhang T; Dong Y; Zhu L; Wang X; Dong Y
    Int J Infect Dis; 2018 Jul; 72():49-54. PubMed ID: 29793038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using Child-Pugh Class to Optimize Voriconazole Dosage Regimens and Improve Safety in Patients with Liver Cirrhosis: Insights from a Population Pharmacokinetic Model-based Analysis.
    Wang T; Yan M; Tang D; Dong Y; Zhu L; Du Q; Sun D; Xing J; Dong Y
    Pharmacotherapy; 2021 Feb; 41(2):172-183. PubMed ID: 33064889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and influencing factor analysis of Voriconazole in the treatment of invasive fungal infections.
    Yang H; Du R; Xing X; Li Y; Qiu B
    Diagn Microbiol Infect Dis; 2023 Nov; 107(3):116047. PubMed ID: 37688949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparing the safety and efficacy of voriconazole versus posaconazole in the prevention of invasive fungal infections in high-risk patients with hematological malignancies.
    Hachem R; Assaf A; Numan Y; Shah P; Jiang Y; Chaftari AM; Raad II
    Int J Antimicrob Agents; 2017 Sep; 50(3):384-388. PubMed ID: 28694233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A retrospective, multicenter study of voriconazole trough concentrations and safety in patients with Child-Pugh class C cirrhosis.
    Wang T; Yan M; Tang D; Xue L; Zhang T; Dong Y; Zhu L; Wang X; Dong Y
    J Clin Pharm Ther; 2018 Dec; 43(6):849-854. PubMed ID: 29893015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylactic administration of voriconazole with two different doses for invasive fungal infection in children and adolescents with acute myeloid leukemia.
    Sano H; Kobayashi R; Hori D; Kishimoto K; Suzuki D; Yasuda K; Kobayashi K
    J Microbiol Immunol Infect; 2018 Apr; 51(2):260-266. PubMed ID: 27329132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Necessity for a Significant Maintenance Dosage Reduction of Voriconazole in Patients with Severe Liver Cirrhosis (Child-Pugh Class C).
    Yamada T; Imai S; Koshizuka Y; Tazawa Y; Kagami K; Tomiyama N; Sugawara R; Yamagami A; Shimamura T; Iseki K
    Biol Pharm Bull; 2018 Jul; 41(7):1112-1118. PubMed ID: 29760306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secondary antifungal prophylaxis in allogeneic hematopoietic stem cell transplant recipients with invasive fungal infection.
    Pepeler MS; Yildiz Ş; Yegin ZA; Özkurt ZN; Tunçcan ÖG; Erbaş G; Köktürk N; Kalkanci A; Yildirim Z
    J Infect Dev Ctries; 2018 Sep; 12(9):799-805. PubMed ID: 31999640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamic studies of voriconazole: informing the clinical management of invasive fungal infections.
    Job KM; Olson J; Stockmann C; Constance JE; Enioutina EY; Rower JE; Linakis MW; Balch AH; Yu T; Liu X; Thorell EA; Sherwin CM
    Expert Rev Anti Infect Ther; 2016 Aug; 14(8):731-46. PubMed ID: 27355512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination antifungals as an effective means of salvage in paediatric leukaemia patients with invasive fungal infections.
    Meena JP; Gupta AK; Jana M; Seth R
    Indian J Med Microbiol; 2019; 37(1):109-112. PubMed ID: 31424020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of voriconazole in the treatment of invasive pulmonary aspergillosis in patients with liver failure: study protocol for a randomized controlled clinical trial.
    Yu X; Xu L; Zheng J; Lei Z; Pang Y; Li X; Zhu J; Liu J
    Trials; 2023 Dec; 24(1):811. PubMed ID: 38105213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantification of 1,3-β-d-glucan by Wako β-glucan assay for rapid exclusion of invasive fungal infections in critical patients: A diagnostic test accuracy study.
    Cento V; Alteri C; Mancini V; Gatti M; Lepera V; Mazza E; Moioli MC; Merli M; Colombo J; Orcese CA; Bielli A; Torri S; Gasparini LE; Vismara C; De Gasperi A; Brioschi P; Puoti M; Cairoli R; Lombardi G; Perno CF
    Mycoses; 2020 Dec; 63(12):1299-1310. PubMed ID: 32810888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cost-effectiveness of isavuconazole compared to the standard of care in the treatment of patients with invasive fungal infection prior to differential pathogen diagnosis in the United Kingdom.
    Floros L; Pagliuca A; Taie AA; Weidlich D; Rita Capparella M; Georgallis M; Sung AH
    J Med Econ; 2020 Jan; 23(1):86-97. PubMed ID: 31262225
    [No Abstract]   [Full Text] [Related]  

  • 16. The incidence of invasive fungal infections in neutropenic patients with acute leukemia and myelodysplastic syndromes receiving primary antifungal prophylaxis with voriconazole.
    Barreto JN; Beach CL; Wolf RC; Merten JA; Tosh PK; Wilson JW; Hogan WJ; Litzow MR
    Am J Hematol; 2013 Apr; 88(4):283-8. PubMed ID: 23460251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Retrospective analysis of risk factors of liver cirrhosis combined with overt hepatic encephalopathy: a single -center case-control study].
    Fan YN; Ji TT; Liang RY; Yu YY; Xu JH
    Zhonghua Gan Zang Bing Za Zhi; 2021 Feb; 29(2):133-136. PubMed ID: 33685081
    [No Abstract]   [Full Text] [Related]  

  • 18. Posaconazole versus voriconazole as antifungal prophylaxis during induction therapy for acute myelogenous leukemia or myelodysplastic syndrome.
    Phillips K; Cirrone F; Ahuja T; Siegfried J; Papadopoulos J
    J Oncol Pharm Pract; 2019 Mar; 25(2):398-403. PubMed ID: 30319061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of intravoxel incoherent motion diffusion-weighted MR imaging for assessment of treatment response to invasive fungal infection in the lung.
    Yan C; Xu J; Xiong W; Wei Q; Feng R; Wu Y; Liu Q; Li C; Chan Q; Xu Y
    Eur Radiol; 2017 Jan; 27(1):212-221. PubMed ID: 27180185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: a prospective study.
    Soler-Palacín P; Frick MA; Martín-Nalda A; Lanaspa M; Pou L; Roselló E; de Heredia CD; Figueras C
    J Antimicrob Chemother; 2012 Mar; 67(3):700-6. PubMed ID: 22190607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.